You just read:

Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series

News provided by

Merrimack Pharmaceuticals, Inc.

May 17, 2016, 16:05 ET